Insider · CIK 0001720685

Katabi Maha

Reports to the SEC for 7 companies · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001720685

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-05-14	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2024-06-05	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+12.5K sh	—	—	12,500
2024-05-15	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2024-03-25	VERAVera Therapeutics, Inc.S Sale	Director	SSale	−340K sh	$40.50	−$13.8M	2,793,987
2024-03-22	VERAVera Therapeutics, Inc.S Sale	Director	SSale	−413K sh	$40.51	−$16.7M	3,133,987
2024-03-21	VERAVera Therapeutics, Inc.S Sale	Director	SSale	−12.6K sh	$45.52	−$574K	3,561,155
2024-03-21	VERAVera Therapeutics, Inc.S Sale	Director	SSale	−13.7K sh	$46.18	−$633K	3,547,437
2024-03-21	VERAVera Therapeutics, Inc.S Sale	Director	SSale	−32.8K sh	$43.00	−$1.41M	3,595,690
2024-03-21	VERAVera Therapeutics, Inc.S Sale	Director	SSale	−21.9K sh	$44.00	−$964K	3,573,772
2024-02-26	RayzeBio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−1.21M sh	$62.50	−$75.6M	0
2024-02-26	RayzeBio, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−18.2K sh	—	—	0
2024-02-26	RayzeBio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−1.21M sh	$62.50	−$75.6M	0
2024-01-30	VERAVera Therapeutics, Inc.P Purchase	Director	PPurchase	+161K sh	$31.00	+$5M	3,628,446
2024-01-02	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+3,519 sh	$13.49	+$47.5K	3,519
2023-11-17	RayzeBio, Inc.Stock Option (right to buy)A Award	Director	AAward	+18.2K sh	—	—	18,235
2023-09-19	RayzeBio, Inc.Series D Convertible Preferred StockC Conversion	Director	CConversion	−974K sh	—	—	0
2023-09-19	RayzeBio, Inc.C Conversion	Director	CConversion	+974K sh	—	—	973,653
2023-09-19	RayzeBio, Inc.C Conversion	Director	CConversion	+974K sh	—	—	973,653
2023-09-19	RayzeBio, Inc.P Purchase	Director	PPurchase	+236K sh	$18.00	+$4.25M	1,209,764
2023-09-19	RayzeBio, Inc.P Purchase	Director	PPurchase	+236K sh	$18.00	+$4.25M	1,209,764
2023-09-19	RayzeBio, Inc.Series D Convertible Preferred StockC Conversion	Director	CConversion	−974K sh	—	—	0
2023-06-06	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+12.5K sh	—	—	12,500
2023-05-10	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2023-01-03	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+2,627 sh	$18.08	+$47.5K	2,627
2022-06-21	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+12.5K sh	—	—	12,500
2022-05-24	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+9,925 sh	—	—	9,925
2022-01-03	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+7,240 sh	$6.56	+$47.5K	7,240
2021-07-02	JBIOJade Biosciences, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−10.6M sh	—	—	0
2021-07-02	JBIOJade Biosciences, Inc.P Purchase	Director, 10% Owner	PPurchase	+357K sh	$14.00	+$5M	3,758,686
2021-07-02	JBIOJade Biosciences, Inc.C Conversion	Director, 10% Owner	CConversion	+3.4M sh	—	—	3,401,544
2021-07-01	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+2,467 sh	$11.15	+$27.5K	2,467
2021-06-29	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+25K sh	—	—	25,000
2021-06-04	JBIOJade Biosciences, Inc. · Series A Preferred StockA Award	Director, 10% Owner	AAward	+8.08M sh	$1.89	+$15.3M	10,565,238
2021-05-18	VERAVera Therapeutics, Inc.P Purchase	Director	PPurchase	+727K sh	$11.00	+$8M	2,914,776
2021-05-18	VERAVera Therapeutics, Inc.C Conversion	Director	CConversion	+2.19M sh	—	—	2,187,504
2021-05-18	VERAVera Therapeutics, Inc. · Series C Preferred StockC Conversion	Director	CConversion	−2.19M sh	—	—	0
2021-05-13	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+9,925 sh	—	—	9,925
2021-02-01	JBIOJade Biosciences, Inc. · Series A Preferred StockA Award	Director, 10% Owner	AAward	+1.16M sh	$1.89	+$2.2M	2,483,048

Recent filings

Accepted (ET)
May 164
Katabi Maha0001415889-25-013423
SEC(opens sec.gov)
Jun 74
Katabi Maha0001415889-24-016056
SEC(opens sec.gov)
May 174
Katabi Maha0001415889-24-013476
SEC(opens sec.gov)
Mar 254
Katabi Maha0001104659-24-038589
SEC(opens sec.gov)
Feb 274
Katabi Maha0001415889-24-005511
SEC(opens sec.gov)
Feb 14
Katabi Maha0001104659-24-009537
SEC(opens sec.gov)
Jan 44
Katabi Maha0001415889-24-000704
SEC(opens sec.gov)
Nov 174
Katabi Maha0001628280-23-039536
SEC(opens sec.gov)
Sep 214
Katabi Maha0001209191-23-050305
SEC(opens sec.gov)

Companies

Address

C/O SOFINNOVA INVESTMENTS, INC. 3000 SAND HILL ROAD, BLDG. 4, SUITE 250

MENLO PARK, CA, 94025